Garrett Winslow was Promoted as General Counsel at Spring-Bank-Pharmaceuticals

Date of management change: January 09, 2018 

What Happened?

Hopkinton, -based Spring-Bank-Pharmaceuticals Promoted Garrett Winslow as General Counsel

 

About the Company

Spring Bank Pharmaceuticals (NASDAQ: SBPH) is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. Spring Bank is developing its most advanced SMNH product candidate, inarigivir soproxil (formerly referred to as SB 9200), for the treatment of viral diseases, including hepatitis B virus (HBV), and other SMNH product candidates, including SB 11285, the company`s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of Interferon Genes, or STING, pathway.

 

About the Person

Garrett Winslow is General Counsel at Spring Bank Pharmaceuticals. Previously, Garrett held various senior legal leadership roles in the industry.

 

Info Source

Press Release

 
 

Other IT executives who recently changed jobs as well: Raybuck Joseph, Horne Denise, Damisch Marcie, Meisgeier Steven, Abrams Amanda, Kunkle Lisa, Perella Dominic, Stanton Sherri, Barbour Bonita, Kwiatkowski Sarah, Frankel Donna

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.